ArticleFrontiers in immunology2026
A conditional multi-signal validation framework for cancer immunotherapy: the adaptive anti-error biological system.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer immunotherapy faces persistent limitations due to its reliance on single-signal therapeutic architectures, which are vulnerable to antigen loss, off-tumor toxicity, and tumor heterogeneity. A fundamental contributor to therapeutic failure is the generation of biological decision errors - false-positive activation in normal tissues and false-negative missed recognition in antigen-low tumors. Objective: We propose the Adaptive Anti-Error Biological System (AABS), a conceptual framework designed to improve therapeutic precision through structured multi-signal validation and conditional effector activation. A simplified implementation, AABS-01, is introduced as a trimodular conditional therapeutic model integrating tumor priming, dual-signal AND-gate logic, and conditional effector engagement. Framework: AABS-01 operates through three coordinated layers: (1) a Tumor Priming Layer enhancing antigen visibility through tumor-restricted IFN-γ conditioning, epigenetic modulation, and TME normalization; (2) a Validation Layer implementing Boolean AND-gate logic requiring simultaneous detection of two independent tumor-associated signals; and (3) an Effector Layer triggering localized immune activation exclusively upon validated dual-signal convergence. Bioinformatic support: Analysis of TCGA Pan-Cancer Atlas and GTEx v8 transcriptomic data confirms that four candidate signal pairs (HER2/MUC4, EGFR/EpCAM, MSLN/HER2, PD-L1/GD2) achieve corrected Tumor Specificity Index (TSI) values of 18.3x to 46.8x across six cancer types, after correction for inter-signal correlation (r = 0.18-0.44). A revised probabilistic framework accounting for signal co-regulation demonstrates that AND-gate logic achieves 3-8x false-positive rate reduction versus single-signal approaches under empirically observed correlation conditions. Conclusion: AABS represents a paradigm shift from reactive to decision-based cancer immunotherapy, grounded in established immunological principles including T-cell multi-signal activation and kinetic proofreading. A five-phase experimental roadmap with quantitative endpoints is provided to guide preclinical and translational validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.